Clinical Trials
37 trialsMetronomic Chemotherapy in a Real-world Population of Advanced Breast Cancer Patients
Sun Yat-sen University
Combination Chemotherapy With Trastuzumab in Treating Women With Metastatic Breast Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer
Indiana University
Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients
Austrian Breast & Colorectal Cancer Study Group
Randomized Study Comparing Pre- and Postoperative vs. Conventional Adjuvant Treatment in Receptor-negative Patients
Austrian Breast & Colorectal Cancer Study Group
Tamoxifen in Treating Women With High-Risk Breast Cancer
Canadian Cancer Trials Group
4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF
West German Study Group
6MP
University of Oxford
Metronomic Low-Dose Cyclophosphamide and Methotrexate With or Without Bevacizumab in Treating Women With Metastatic Breast Cancer
Dana-Farber Cancer Institute
Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery
University of Washington
Liposomal Cytarabine and High-Dose Methotrexate in Treating Patients With Central Nervous System Metastases From Breast Cancer
University of Washington
ELDA: Elderly Breast Cancer - Docetaxel in Adjuvant Treatment
National Cancer Institute, Naples
Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer
Memorial Sloan Kettering Cancer Center
22-00
ETOP IBCSG Partners Foundation
Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE)
GBG Forschungs GmbH
ICE-II
GBG Forschungs GmbH
Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in Women With Operable Breast Cancer
Dana-Farber Cancer Institute
Combination Chemotherapy With or Without Epirubicin in Treating Women With Stage I or Stage II Breast Cancer
National Cancer Institute (NCI)
Adjuvant Chemotherapy Plus Radiation Therapy in Treating Women With Early-Stage Breast Cancer
National Cancer Institute (NCI)
ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer
Dana-Farber Cancer Institute
Tamoxifen Following Combination Chemotherapy in Treating Women With Operable Invasive Breast Cancer
National Cancer Institute (NCI)
Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast Cancer
National Cancer Institute (NCI)
Tamoxifen With or Without Combination Chemotherapy in Treating Postmenopausal Women With Operable Invasive Breast Cancer
National Cancer Institute (NCI)
Standard Chemotherapy Compared With High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer
National Cancer Institute (NCI)
Combination Chemotherapy Following Surgery in Treating Women With Early Stage Breast Cancer
National Cancer Institute (NCI)
Bevacizumab With Etoposide and Cisplatin in Breast Cancer Patients With Brain and/or Leptomeningeal Metastasis
National Taiwan University Hospital
Chemotherapy Plus Surgery in Treating Women With Breast Cancer
National Cancer Institute (NCI)
Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer
National Cancer Institute (NCI)
Triptorelin in Preventing Early Menopause in Premenopausal Women Who Are Receiving Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery
National Cancer Institute (NCI)
15-95
ETOP IBCSG Partners Foundation
Chemotherapy Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer
Case Comprehensive Cancer Center
The Comparative Trial of UFT + TAM With CMF + TAM in Adjuvant Therapy for Breast Cancer (CUBC)
Taiho Pharmaceutical Co., Ltd.
A Randomized Controlled Study of Postoperative Adjuvant Therapy of Uracil-tegafur (UFT) Compared With Cyclophosphamide/Methotrexate/5-fluorouracil (CMF) in Breast Cancer (NSAS-BC)
Taiho Pharmaceutical Co., Ltd.
Weekly Docetaxel and CMF in the Adjuvant Treatment of Elderly Women With High-Risk Breast Cancer
SCRI Development Innovations, LLC
A Study of Cyclophosphamide/Methotrexate/5-Fluorouracil (CMF) With Pegfilgrastim in Subjects With Breast Cancer
Amgen
Study of Docetaxel in Breast Cancer Patients
Sanofi
A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer
National Institutes of Health Clinical Center (CC)